טוען...
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
About 25% of breast cancers harbor the amplified oncogene HER2 and are dependent on HER2 kinase function, identifying HER2 as a vulnerable target for therapy. However,. HER2-HER3 activation is buffered so that it is protected against a nearly two log inhibition of HER2 catalytic activity; this buffe...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3033659/ https://ncbi.nlm.nih.gov/pubmed/20371474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3000389 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|